制酸剤の世界市場：現状分析と予測（2022年～2028年）

世界の制酸剤の市場規模は、2022年～2028年にCAGRで約9%の成長が予測されています。市場の成長は、高齢者人口の拡大や、びらん性食道炎、バレット食道、食道がんなどの胃食道逆流症（GERD）の増加、消費者の胃腸の健康に対する意識などに起因しています。

当レポートでは、世界の制酸剤市場について調査分析し、市場規模と予測分析、主な動向と機会、企業プロファイルなどの情報を提供しています。

目次

第1章 市場のイントロダクション

第2章 調査手法・前提条件

第3章 市場の要約

第4章 エグゼクティブサマリー

第5章 世界の制酸剤市場のCOVID-19の影響

第6章 世界の制酸剤市場の収益（2020年～2028年）

第7章 市場の考察：医薬品クラス別

• プロトンポンプ阻害薬
• H2拮抗薬
• 酸中和剤
• その他

第8章 市場の考察：剤型別

• 錠剤
• カプセル
• 懸濁液
• ドロップ
• その他

第9章 市場の考察：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局
• その他

第10章 市場の考察：地域別

• 北米
  • 米国
  • カナダ
  • その他の北米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • その他のアジア太平洋
• その他の地域

第11章 制酸剤の市場力学

• 市場促進要因
• 市場の課題
• 影響の分析

第12章 制酸剤市場の機会

第13章 制酸剤市場の動向

第14章 政策と規制の枠組み

第15章 デマンド・サプライサイド分析

• デマンドサイド分析
• サプライサイド分析

第16章 バリューチェーン分析

第17章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第18章 企業の概要

• GlaxoSmithKline plc.
• Pfizer Inc.
• Bayer AG
• Dr. Reddy's Laboratories Ltd.
• AstraZeneca PLC.
• Boehringer Ingelheim GmbH
• Sun Pharmaceuticals Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Abbott Laboratories
• Johnson & Johnson

第19章 免責事項

The global antacids market is experiencing significant growth due to the increasing aging population and Gastroesophageal Reflux Disease (GERD), such as erosive esophagitis, Barrett esophagus, and esophageal cancer amongst the population, and awareness regarding gastrointestinal health among consumers. For Instance, In March 2020, Lupin launched the authorized generic for Horizon Therapeutics PLC's Vimovo (naproxen/esomeprazole magnesium) delayed-release tablets in the United States. The product is a combination of naproxen, and esomeprazole magnesium, in which naproxen is used for symptomatic relief of arthritis and esomeprazole magnesium to decrease the risk of developing naproxen-associated gastric ulcers. Furthermore, PLC's Vimovo is used when quick relief of your symptoms is required. Therefore, the market for antacids is expected to witness a significant CAGR of 9% during the forecast period.

Global Antacids Market is expected to register a CAGR of around 9% over the period of 2022-2028. This is mainly due to the growing geriatric population suffering from Gastroesophageal Reflux Disease (GERD), which occurs due to higher incidences of acidity, that results in the side effects of drugs like non-steroidal, anti-inflammatory drugs., and stringent government regulations coupled with the growing focus of major stakeholders in the healthcare industry to adopt to make antacids products more sustainable with fewer side effects and cost-effective. Major healthcare companies are investing heavily in their products due to rising social awareness regarding gastrointestinal cases, and other associated disorders, such as erosive esophagitis, Barrett esophagus, and esophageal cancer. According to World Gastroenterology Organization, the prevalence of GERD is increasing worldwide and ranges from nearly 2.5% to 6.6% in Eastern Asia and nearly 13.8% to 25.8% in North America. This rise in the prevalence of these disorders is contributing to market growth. Furthermore, many therapies are used for the treatment and the use of antacids significantly rises in such cases which is responsible for excessive use of antacids and also significantly contributes to the market for antacids. Therefore, the market for antacids is expected to witness significant growth during the forecast period.

GlaxoSmithKline plc., Pfizer Inc., Bayer AG, Dr. Reddy's Laboratories Ltd., AstraZeneca PLC., Boehringer Ingelheim GmbH, Sun Pharmaceuticals Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Johnson & Johnson are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst Drug Class, proton pump inhibitors category accounted for the majority share in the market in 2020"

Based on drug class, the market is classified into proton pump inhibitors, H2 antagonists, acid neutralizers and others. Amongst types, the proton pump inhibitors category accounted for a significant share of the market. This is mainly due to its use in the treatment of gastroesophageal reflux disease (also known as GERD). This class is considered standard antacids and this type of drug reduce stomach acid production significantly and for a long time. This segment's dominance is attributable to the presence of a large number of proton pump inhibitor antacids in the global market.

"Amongst Formulation, tablets are expected to witness highest CAGR during the forecast period"

Based on formulation, the market is categorized into tablets, capsules, suspension, drops, and others. Among these, the tablet is expected to witness the highest CAGR during the forecast period. This is mainly due to the strong prevalence of the presence of a variety of chewable tablets in the market with different flavors that help to improve patient adherence to the medication. Furthermore, supportive government initiatives to create awareness regarding the treatment options for gastric issues are expected to well for the adoption of innovative drugs. The continuous development of the new products and procedures is likely to strengthen the market of the segment during the forecast period.

"North America to witness significant growth during the forecast period"

North America is expected to show the highest CAGR growth in the antacids market. The major contributors to the growth of this market are US and Canada. The increase in technology development in emerging economies, as well as the expansion of the healthcare industry, has contributed to the growth of the North America market. North America has a higher adoption rate of medical treatment and antacid drugs. The enhanced awareness regarding the availability of various antacids has propelled the growth of the market in the region. Hence these require drugs in the region which drives the demand for antacids in the region. Furthermore, increasing geriatric population and new product launches, and various developmental strategies adopted by the regional market will drive market growth. Furthermore, according to the Centers for Disease Control and Prevention (CDC) 2018 statistics, the total number of adults diagnosed with ulcers in the United States was found to be 14.8 million. The number of populations with ulcers is proportional to the population suffering from GERD. Furthermore, the biopharmaceutical companies and diagnostics industry owing to the presence of well-established market players and frequent product launches in the region.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

Global antacids market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Antacids Market
• 2.2. Research Methodology of the Antacids Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL ANTACIDS MARKET COVID-19 IMPACT

6 GLOBAL ANTACIDS MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY DRUG CLASS

• 7.1. Proton pump inhibitors
• 7.2. H2 antagonist
• 7.3. Acid neutralizers
• 7.4. Others

8 MARKET INSIGHTS BY FORMULATION

• 8.1. Tablets
• 8.2. Capsules
• 8.3. Suspension
• 8.4. Drops
• 8.5. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Hospital Pharmacies
• 9.2. Retail Pharmacies
• 9.3. Online Pharmacies
• 9.4. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. UK
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Australia
  • 10.3.5. Rest of Asia-Pacific
• 10.4. Rest of World

11 ANTACIDS MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 ANTACIDS MARKET OPPORTUNITIES

13 ANTACIDS MARKET TRENDS

14 POLICY & REGULATORY FRAMEWORK

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porter's Five Forces Analysis

18 COMPANY PROFILED

• 18.1. GlaxoSmithKline plc.
• 18.2. Pfizer Inc.
• 18.3. Bayer AG
• 18.4. Dr. Reddy's Laboratories Ltd.
• 18.5. AstraZeneca PLC.
• 18.6. Boehringer Ingelheim GmbH
• 18.7. Sun Pharmaceuticals Industries Ltd.
• 18.8. Takeda Pharmaceutical Company Limited
• 18.9. Abbott Laboratories
• 18.10. Johnson & Johnson

19 DISCLAIMER